Background of Actemra
Actemra is an anti-rheumatic drug often prescribed to persons battling RA (rheumatoid arthritis), an autoimmune condition characterized by joint swelling. This drug belongs to a class known as IL-6 (interleukin-6) inhibitors which function by suppressing activity of the IL-6 (interleukin-6) protein that contributes to swelling.
Since being approved by the FDA in 2010, Actemra has quickly become a go-to treatment option for patients living with RA, as it has proven its ability to effectively reduce joint soreness and stiffness while improving physical function and slowing disease progression.
But recently, there have been concerns raised regarding its safety. One major concern is the risk of severe infections such as pneumonia and sepsis, which can result in hospitalization and even death. In 2017, the FDA issued a safety alert alerting healthcare providers and patients of its higher infection risks than observed with similar drugs such as Actemra.
As more lawsuits against Actemra’s manufacturer continue to arise, those affected have sought legal guidance. If you may have been affected by Actemra, it is vital to understand its potential risks as well as seek guidance from an experienced attorney if possible.
